Specific labelling by [125I]helodermin of high-affinity VIP receptors in rat liver membranes. 1984

P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe

Helodermin, a newly isolated peptide from Gila Monster venom, is structurally related to VIP and secretin. When used as radioligand, [125I]helodermin bound rapidly and reversibly to crude rat liver membranes, the dissociation being accelerated by GTP. Competition binding curves of [125I]helodermin and [125I]VIP with unlabelled peptides showed the following order of decreasing affinity: VIP greater than helodermin greater than secretin greater than hpGRF(1-29)-NH2. The shape of binding curves and of concurrent adenylate cyclase activation is compatible with the specific labelling, by [125I]helodermin, of a class of high-affinity VIP receptors that is capable to stimulate adenylate cyclase.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008116 Lizards Reptiles within the order Squamata that generally possess limbs, moveable EYELIDS, and EXTERNAL EAR openings, although there are some species which lack one or more of these structures. Chameleons,Geckos,Chameleon,Gecko,Lizard
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006160 Guanosine Triphosphate Guanosine 5'-(tetrahydrogen triphosphate). A guanine nucleotide containing three phosphate groups esterified to the sugar moiety. GTP,Triphosphate, Guanosine
D000262 Adenylyl Cyclases Enzymes of the lyase class that catalyze the formation of CYCLIC AMP and pyrophosphate from ATP. Adenyl Cyclase,Adenylate Cyclase,3',5'-cyclic AMP Synthetase,Adenylyl Cyclase,3',5' cyclic AMP Synthetase,AMP Synthetase, 3',5'-cyclic,Cyclase, Adenyl,Cyclase, Adenylate,Cyclase, Adenylyl,Cyclases, Adenylyl,Synthetase, 3',5'-cyclic AMP

Related Publications

P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
May 1988, European journal of pharmacology,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
January 1991, The American journal of physiology,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
July 1996, Regulatory peptides,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
January 1986, Peptides,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
August 1989, European journal of pharmacology,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
June 1989, The Biochemical journal,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
January 1977, The Journal of clinical investigation,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
October 1984, Neuropharmacology,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
January 1977, Biochemical and biophysical research communications,
P Robberecht, and M Waelbroeck, and P de Neef, and J C Camus, and A Vandermeers, and M C Vandermeers-Piret, and J Christophe
April 1984, Biochemical and biophysical research communications,
Copied contents to your clipboard!